Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke

Study acronym: ARTS-SAFE
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 30 days later Sep 30, 2026 → Oct 30, 2026
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from Beijing Tiantan Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 8 more changesShow less
    • Recruitment opened
    • Primary completion pushed from Sep 30, 2026 to Oct 30, 2026
    • Trial sites expanded: 1 → 6 locations
    • Study completion pushed from Dec 31, 2026 to Jan 30, 2027
    • Start date changed from estimate of Mar 1, 2026 to Apr 8, 2026
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints revised (12)
    • Study description revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Beijing Tiantan Hospital
281 trials monitored
See 10 trials at risk
Stroke
3,537 trials monitored
See 161 trials at risk
The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to explore the safety and efficacy of different dose of Anakinra compared to standard medical care for patients with acute ischemic stroke who have achieved successful recanalization after endovascular thrombectomy.
Trial Details
NCT Number NCT07423975
Lead Sponsor Beijing Tiantan Hospital
Conditions
(from sponsor)		 Stroke Acute, Endovascular Treatment
Related terms Ischemic Stroke, Stroke
Enrollment 159 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov